Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

View Full Paper
Ask AI
Bookmark
Share

Authors

BRBrett M. ReidCFChristopher FerreriSAShebli Atrash

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals Parkinsonism and immune-mediated adverse events as risk factors in patients receiving cilta-cel therapy.

Key Points

  • Non-relapse mortality is notably impacted by immune-mediated adverse events, particularly in high-risk patients.
  • Increasing peak absolute lymphocyte count is linked to Parkinsonism risk, with values above 3000/uL showing a 12% absolute risk.
  • Multivariable analysis identified performance status and non-response to bridging therapy as key predictors of outcomes.
  • This research suggests targeting peak ALC and improving bridging strategies may reduce neurotoxicity and mortality.

Cite This Study

Reid et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d455https://doi.org/10.1182/blood-2025-1034
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma2025 · 4 citations
  2. 2Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma2025
  3. 3Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma2025 · 5 citations
  4. 4Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma2025
  5. 5Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma2025 · 9 citations